Search

Your search keyword '"Luminari, S"' showing total 507 results
Start Over Author "Luminari, S"
507 results on '"Luminari, S"'

1. Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma

Author

Kim, T.M., Taszner, M., Novelli, S., Cho, S-G., Villasboas, J.C., Merli, M., Jiménez-Ubieto, A., Tessoulin, B., Poon, L.M., Tucker, D., Walewski, J., Yi, S., Song, Y., Chong, G., Bachy, E., Guidez, S., Alonso, A., Jagadeesh, D., Zhang, W., Magnano, L., Iskierka-Jażdżewska, E., Tani, M., Shen, B., Uppala, A., Zhu, M., Shariff, S., Brouwer-Visser, J., Chaudhry, A., Mohamed, H., Ambati, S., and Luminari, S.

Published
2024
Full Text
View/download PDF

2. Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial

Author

Ladetto, M., Tavarozzi, R., Zanni, M., Evangelista, A., Ferrero, S., Tucci, A., Botto, B., Bolis, S., Volpetti, S., Zilioli, V.R., Puccini, B., Arcari, A., Pavone, V., Gaidano, G., Corradini, P., Tani, M., Cavallo, F., Milone, G., Ghiggi, C., Pinto, A., Pastore, D., Ferreri, A.J.M., Latte, G., Patti, C., Re, F., Benedetti, F., Luminari, S., Pennese, E., Bossi, E., Boccomini, C., Anastasia, A., Bottelli, C., Ciccone, G., and Vitolo, U.

Published
2024
Full Text
View/download PDF

3. Long‐term outcome of peripheral T‐cell lymphomas: Ten‐year follow‐up of the International Prospective T‐cell Project

Author

Civallero, M., primary, Schroers‐Martin, J. G., additional, Horwitz, S., additional, Manni, M., additional, Stepanishyna, Y., additional, Cabrera, M. E., additional, Vose, J., additional, Spina, M., additional, Hitz, F., additional, Nagler, A., additional, Montoto, S., additional, Chiattone, C., additional, Skrypets, T., additional, Perez Saenz, M. A., additional, Priolo, G., additional, Luminari, S., additional, Lymboussaki, A., additional, Pavlovsky, A., additional, Marino, D., additional, Liberati, M., additional, Trotman, J., additional, Mannina, D., additional, Federico, M., additional, and Advani, R., additional

Published
2024
Full Text
View/download PDF

4. End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial

Author

Guerra, L, Chauvie, S, Fallanca, F, Bergesio, F, Marcheselli, L, Durmo, R, Peano, S, Franceschetto, A, Monaco, L, Barbieri, E, Ladetto, M, Musuraca, G, Tosi, P, Bianchi, B, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Califano, C, Bari, A, Massaia, M, Conconi, A, Musto, P, Mannina, D, Roti, G, Galimberti, S, Gini, G, Falcinelli, F, Vitolo, U, Usai, S, Stefani, P, Ibatici, A, Liberati, A, Pennese, E, Perrone, T, Versari, A, Luminari, S, Guerra, Luca, Chauvie, Stephane, Fallanca, Federico, Bergesio, Fabrizio, Marcheselli, Luigi, Durmo, Rexhep, Peano, Simona, Franceschetto, Antonella, Monaco, Lavinia, Barbieri, Emiliano, Ladetto, Marco, Musuraca, Gerardo, Tosi, Patrizia, Bianchi, Benedetta, Bolis, Silvia Anna Maria, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Califano, Catello, Bari, Alessia, Massaia, Massimo, Conconi, Annarita, Musto, Pellegrino, Mannina, Donato, Roti, Giovanni, Galimberti, Sara, Gini, Guido, Falcinelli, Flavio, Vitolo, Umberto, Usai, Sara Veronica, Stefani, Piero Maria, Ibatici, Adalberto, Liberati, Anna Marina, Pennese, Elsa, Perrone, Tommasina, Versari, Annibale, Luminari, Stefano, Guerra, L, Chauvie, S, Fallanca, F, Bergesio, F, Marcheselli, L, Durmo, R, Peano, S, Franceschetto, A, Monaco, L, Barbieri, E, Ladetto, M, Musuraca, G, Tosi, P, Bianchi, B, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Califano, C, Bari, A, Massaia, M, Conconi, A, Musto, P, Mannina, D, Roti, G, Galimberti, S, Gini, G, Falcinelli, F, Vitolo, U, Usai, S, Stefani, P, Ibatici, A, Liberati, A, Pennese, E, Perrone, T, Versari, A, Luminari, S, Guerra, Luca, Chauvie, Stephane, Fallanca, Federico, Bergesio, Fabrizio, Marcheselli, Luigi, Durmo, Rexhep, Peano, Simona, Franceschetto, Antonella, Monaco, Lavinia, Barbieri, Emiliano, Ladetto, Marco, Musuraca, Gerardo, Tosi, Patrizia, Bianchi, Benedetta, Bolis, Silvia Anna Maria, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Califano, Catello, Bari, Alessia, Massaia, Massimo, Conconi, Annarita, Musto, Pellegrino, Mannina, Donato, Roti, Giovanni, Galimberti, Sara, Gini, Guido, Falcinelli, Flavio, Vitolo, Umberto, Usai, Sara Veronica, Stefani, Piero Maria, Ibatici, Adalberto, Liberati, Anna Marina, Pennese, Elsa, Perrone, Tommasina, Versari, Annibale, and Luminari, Stefano

Abstract

Purpose: To evaluate the reliability of the Deauville score (DS) in therapy response assessment and to define the prognostic value of the metabolic response of end of induction (EOI) [18F]FDG PET (PET) in follicular lymphoma patients. Methods: Adult patients with untreated grade 1-3a FL/ stage II-IV enrolled in the multicentre, prospective, phase III FOLL12 trial (NCT02063685) were randomized to receive standard immunochemotherapy followed by rituximab maintenance (standard arm) versus standard immunochemotherapy followed by response-adapted post-induction management (experimental arm). Baseline and EOI PET were mandatory for the study. All PET scans were centralized on the WIDEN® platform and classified according to DS in a blind independent central review. DS1-3 was considered negative (CMR), whereas DS4-5 was considered positive (not CMR). The primary endpoint was PFS. The main secondary endpoint was overall survival (OS). Results: Overall, 807 follicular lymphoma patients-52% women, 89% stage III-IV disease, 40% with a high-risk FLIPI-2 score (3-5)-were enrolled in the study; 729 (90.4%) baseline and EOI PET were available for the analysis. EOI PET was positive (DS4-5) in 88/729 (12.1%) cases. Overall inter-reviewer agreement on PET pos/neg result was 0.92, while agreement on positive and negative cases was 0.77 and 0.94, respectively. The median follow-up was 69 months; 247 events were registered in the 5-yr follow-up, with a 5-yr PFS of 67% (95%CI: 63%-70%). The 5-yr PFS rate for PET neg (DS1-3) and PET pos (DS4-5) patients was 71% (95%CI: 67%-75%) and 36% (95%CI: 25%-46%), respectively, with HR 3.49 (95%CI: 2.57-4.72). Five-year PFS was worse as DS increased, with 74% (70%-78%), 58% (48%-67%; HR 1.71; p = 0.001)] and 36% (25%-46%; HR 3.88; p < 0.001) in DS1-2, DS3 and DS4-5, respectively. EOI PET maintained its prognostic value in both the standard and experimental arms. In the whole population, 5-yr OS was 94% (95%CI: 92%-96%), with 96% (95%CI: 94-97

Published
2024

5. Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial

Author

Ladetto, M., primary, Tavarozzi, R., additional, Zanni, M., additional, Evangelista, A., additional, Ferrero, S., additional, Tucci, A., additional, Botto, B., additional, Bolis, S., additional, Volpetti, S., additional, Zilioli, V.R., additional, Puccini, B., additional, Arcari, A., additional, Pavone, V., additional, Gaidano, G., additional, Corradini, P., additional, Tani, M., additional, Cavallo, F., additional, Milone, G., additional, Ghiggi, C., additional, Pinto, A., additional, Pastore, D., additional, Ferreri, A.J.M., additional, Latte, G., additional, Patti, C., additional, Re, F., additional, Benedetti, F., additional, Luminari, S., additional, Pennese, E., additional, Bossi, E., additional, Boccomini, C., additional, Anastasia, A., additional, Bottelli, C., additional, Ciccone, G., additional, and Vitolo, U., additional

Published
2023
Full Text
View/download PDF

6. ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2

Author

Novelli, S., primary, Luminari, S., additional, Taszner, M., additional, Cho, S., additional, Le Gouill, S., additional, Poon, M., additional, Villasboas, J. C., additional, Champion, R., additional, Bachy, E., additional, Guidez, S., additional, Alonso, A., additional, Jagadeesh, D., additional, Merli, M., additional, Tucker, D., additional, Cai, J., additional, Leite de Oliveira, C., additional, Zhu, M., additional, Chaudhry, A., additional, Mohamed, H., additional, Ambati, S., additional, and Kim, T. M., additional

Published
2023
Full Text
View/download PDF

7. RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED SPLENIC AND NODAL MARGINAL ZONE LYMPHOMAS: PLANNED SUBSET ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY

Author

Thieblemont, C., primary, Lamy, T., additional, Tani, M., additional, Krzisch, D., additional, Reda, G., additional, Tedeschi, A., additional, Usai, S. V., additional, Guarini, A., additional, Bijou, F., additional, Stathis, A., additional, Anastasia, A., additional, Devizzi, L., additional, Luminari, S., additional, Arcaini, L., additional, Casasnovas, O., additional, Gressin, R., additional, André, M., additional, Houot, R., additional, Bonomini, L., additional, Zucca, E., additional, and Conconi, A., additional

Published
2023
Full Text
View/download PDF

8. Baseline PET Total Metabolic Tumor Volume has a prognostic role in PTCLs—Data from International Prospective T‐Cell Project 2.0

Author

Skrypets, T., primary, Chauvie, S., additional, Manni, M., additional, Fallanca, F., additional, Racca, M., additional, Hitz, F., additional, Advani, R., additional, Ramos, C. D., additional, Miranda, E., additional, Tomuleasa, C., additional, Minoia, C., additional, Marino, D., additional, Noyan‐Atalay, F., additional, Stepanishyna, Y., additional, De Maggi, A., additional, Marcheselli, L., additional, Chang, C., additional, Federico, M., additional, and Luminari, S., additional

Published
2023
Full Text
View/download PDF

10. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia

Author

Buske, C., Dreyling, M., Ferreri, A.J.M., Fields, P., Gaidano, G., Goede, V., Hutchings, M., Ladetto, M., Gouill, S.L., Luminari, S., Mey, U., Brown, P.d.N., Pfreundschuh, M., Pott, C., Schmitz, N., Soubeyran, P., Spina, M., Stauder, R., Balari, A.S., Trněný, M., Imhoff, G.v., Walewski, J., Wedding, U., Zamò, A., Zucca, E., and Le Gouill, S.

Published
2016
Full Text
View/download PDF

12. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi

Author

Arcaini, L., Vallisa, D., Rattotti, S., Ferretti, V.V., Ferreri, A.J.M., Bernuzzi, P., Merli, M., Varettoni, M., Chiappella, A., Ambrosetti, A., Tucci, A., Rusconi, C., Visco, C., Spina, M., Cabras, G., Luminari, S., Tucci, M., Musto, P., Ladetto, M., Merli, F., Stelitano, C., d'Arco, A., Rigacci, L., Levis, A., Rossi, D., Spedini, P., Mancuso, S., Marino, D., Bruno, R., Baldini, L., and Pulsoni, A.

Published
2014
Full Text
View/download PDF

13. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)

Author

Luminari, S., Biasoli, I., Versari, A., Rattotti, S., Bottelli, C., Rusconi, C., Merli, F., Spina, M., Ferreri, A.J.M., Zinzani, P.L., Gallamini, A., Franceschetto, A., Boccomini, C., Franceschetti, S., Salvi, F., Raimondo, F.D., Carella, A.M., Micol, Q., Balzarotti, M., Musto, P., and Federico, M.

Published
2014
Full Text
View/download PDF

16. ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project

Author

Shustov, A., Cabrera, M. E., Civallero, M., Bellei, M., Y. H., Ko, Manni, M., Skrypets, T., Horwitz, S. M., de Souza, C. A., Radford, J. A., Bobillo, S., Prates, M. V., Ferreri, A. J. M., Chiattone, C., Spina, M., Vose, J. M., Chiappella, A., Laszlo, D., Marino, D., Stelitano, C., Federico, M., Savage, K., Connors, J., Gascoyne, R., Chhanabhai, M., Wilson, W., Jaffe, E. S., Armitage, J. O., Weisenburger, D. D., Anderson, J., Ullrich, F., Bast, M., Hochberg, E., Harris, N., Smogorzews ka, A., Levine, A., Nathwani, B. N., Miller, T., Rimsza, L., Montserrat, E., Lopez-Guillermo, A., Campo, E., Cuadros, M., Ferreira, J. A., Delgado, B. M., Holte, H., Delabie, J., Rudiger, T., Muller-Hermelink, K., Reimer, P., Adam, P., Wilhelm, M., Schmitz, N., Nerl, C., Lister, A., Norton, A., Maclennan, K. A., Zinzani, P. L., Pileri, S. A., Bellai, M., Luminari, S., Coiffier, B., Berger, F., Tanin, I., Wannakrairot, P., W. Y., Au, Liang, R., Loong, F., Rajan, S., Sng, I., Tobinai, K., Matsuno, Y., Morishima, Y., Nakamura, S., Seto, M., Tanimoto, M., Yoshino, T., Suzumiya, J., Ohshima, K., and Kim, W. -S.

Subjects
Male, Oncology, medicine.medical_specialty, Anaplastic Lymphoma, Clinical Trials and Observations, T-Lymphocytes, medicine.medical_treatment, International Prognostic Index, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Anaplastic Lymphoma Kinase, Prospective Studies, Prospective cohort study, Anaplastic large-cell lymphoma, Etoposide, Retrospective Studies, Chemotherapy, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Receptor Protein-Tyrosine Kinases, Hematology, medicine.disease, Lymphoma, Transplantation, Lymphoma, Large-Cell, Anaplastic, Female, business, medicine.drug
Abstract

Anaplastic lymphoma kinase–negative anaplastic large cell lymphoma (ALK– ALCL) is an aggressive neoplasm of T-cell/null-cell lineage. The T-Cell Project is a global prospective cohort study that consecutively enrolled patients newly diagnosed with peripheral T-cell lymphoma, registered through a centralized computer database between September 2006 and February 2018. Of 1553 validated cases from 74 sites in 13 countries worldwide, 235 were reported as ALK– ALCL. The median age at diagnosis was 54 years (range, 18-89 years), with a male predominance (62%). Stage III to IV disease was identified in 71% of patients, bulky disease and bone marrow involvement were uncommon, and 66% of patients presented with a low (0-1) International Prognostic Index score. Of all treated patients, 85% received multiagent initial chemotherapy, and 8% were consolidated with autologous hematopoietic cell transplantation. The initial overall and complete response rates were 77% and 63%, respectively. After a median follow-up of 52 months (95% confidence interval [CI], 41-63), the median progression-free survival (PFS) and overall survival (OS) were 41 months (95% CI, 17-62) and 55 months (95% CI, 36-75), respectively. The 3- and 5-year PFS rates were 52% and 43%, and the 3- and 5-year OS rates were 60% and 49%. Treatments containing both anthracycline and etoposide were associated with superior OS (P = .05) but not PFS (P = .18). In this large prospective cohort study, outcomes comparable to those previously reported in the retrospective International Peripheral T-Cell Lymphoma Project were observed. The study underscores the need for introducing novel platforms for ALK– ALCL and establishes a benchmark for future clinical trials. This trial was registered at www.clinicaltrials.gov as #NCT01142674.

Published
2021
Full Text
View/download PDF

17. P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)

Author

Sehn, L. H., primary, Hübel, K., additional, Luminari, S., additional, Salar, A., additional, Wahlin, B. E., additional, Gopal, A. K., additional, Bonnet, C., additional, Paneesha, S., additional, Trneny, M., additional, Mashegu, H., additional, Lihou, C., additional, Li, D., additional, and Scholz, C. W., additional

Published
2022
Full Text
View/download PDF

18. P1144: RADIOIMMUNOTHERAPY (RIT) VERSUS AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ASCT) IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA: A FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III TRIAL.

Author

Ladetto, M., primary, Tavarozzi, R., additional, Evangelista, A., additional, Zanni, M., additional, Tucci, A., additional, Anastasia, A., additional, Botto, B., additional, Boccomini, C., additional, Bolis, S., additional, Volpetti, S., additional, Zilioli, V. R., additional, Puccini, B., additional, Arcari, A., additional, Pavone, V., additional, Gaidano, G., additional, Corradini, P., additional, Tani, M., additional, Ferrero, S., additional, Cavallo, F., additional, Milone, G., additional, Ghiggi, C., additional, Pinto, A., additional, Pastore, D., additional, Ferreri, A. J., additional, Latte, G., additional, Patti, C., additional, Re, F., additional, Arcaini, L., additional, Benedetti, F., additional, Usai, S. V., additional, Luminari, S., additional, Mannina, D., additional, Pulsoni, A., additional, Stelitano, C., additional, Pennese, E., additional, Pietrantuono, G., additional, Gherlinzoni, F., additional, Pomponi, F., additional, Olivieri, A., additional, Perrone, T., additional, Rota Scalabrini, D., additional, Califano, C., additional, Falini, B., additional, Ciccone, G., additional, and Vitolo, U., additional

Published
2022
Full Text
View/download PDF

19. P1208: CHARACTERISTICS AND CLINICAL OUTCOMES OF PATIENTS WITH ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA: REPORT FROM THE PROSPECTIVE INTERNATIONAL T-CELL LYMPHOMA PROJECT

Author

Chiattone, C., primary, Civallero, M., additional, Fischer, T., additional, Miranda, E., additional, Manni, M., additional, Zing, N. P. C., additional, Pileri, S. A., additional, Montoto, S., additional, Horwitz, S. M., additional, Cabrera, M. E., additional, De Souza, C. A., additional, Nagler, A., additional, Luminari, S., additional, Ferreri, A. J. M., additional, Carson, K. R., additional, Re, A., additional, Rigacci, L., additional, Nassi, L., additional, Federico, M., additional, and Inghirami, G., additional

Published
2022
Full Text
View/download PDF

20. S222: MATURE T AND NK CELL LYMPHOMAS CLASSIFIED ACCORDING TO 2016 WHO CLASSIFICATION. A REPORT OF THE INTERNATIONAL PROSPECTIVE T-CELL PROJECT 2.0.

Author

Federico, M., primary, Stepanishyna, Y., additional, Skrypets, T., additional, Chiattone, C. S., additional, Prince, M. H., additional, Pavlovsky, A., additional, Lymboussakis, A., additional, Manni, M., additional, Civallero, M., additional, de Souza, C. A., additional, Hawkes, E. A., additional, Fiad, L., additional, Nair, R., additional, Kriachok, I., additional, Hitz, F., additional, Kostina, O., additional, Tomuleasa, C., additional, Guarini, A., additional, and Luminari, S., additional

Published
2022
Full Text
View/download PDF

21. Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study

Author

Luminari, S, Manni, M, Galimberti, S, Versari, A, Tucci, A, Boccomini, C, Farina, L, Olivieri, J, Marcheselli, L, Guerra, L, Ferrero, S, Arcaini, L, Cavallo, F, Kovalchuk, S, Skrypets, T, Del Giudice, I, Chauvie, S, Patti, C, Stelitano, C, Ricci, F, Pinto, A, Margiotta Casaluci, G, Zilioli, V, Merli, A, Ladetto, M, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Anastasia, A, Dondi, A, Mannina, D, Federico, M, Luminari, Stefano, Manni, Martina, Galimberti, Sara, Versari, Annibale, Tucci, Alessandra, Boccomini, Carola, Farina, Lucia, Olivieri, Jacopo, Marcheselli, Luigi, Guerra, Luca, Ferrero, Simone, Arcaini, Luca, Cavallo, Federica, Kovalchuk, Sofya, Skrypets, Tetiana, Del Giudice, Ilaria, Chauvie, Stephane, Patti, Caterina, Stelitano, Caterina, Ricci, Francesca, Pinto, Antonello, Margiotta Casaluci, Gloria, Zilioli, Vittorio R, Merli, Anna, Ladetto, Marco, Bolis, Silvia, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Anastasia, Antonella, Dondi, Alessandra, Mannina, Donato, Federico, Massimo, Luminari, S, Manni, M, Galimberti, S, Versari, A, Tucci, A, Boccomini, C, Farina, L, Olivieri, J, Marcheselli, L, Guerra, L, Ferrero, S, Arcaini, L, Cavallo, F, Kovalchuk, S, Skrypets, T, Del Giudice, I, Chauvie, S, Patti, C, Stelitano, C, Ricci, F, Pinto, A, Margiotta Casaluci, G, Zilioli, V, Merli, A, Ladetto, M, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Anastasia, A, Dondi, A, Mannina, D, Federico, M, Luminari, Stefano, Manni, Martina, Galimberti, Sara, Versari, Annibale, Tucci, Alessandra, Boccomini, Carola, Farina, Lucia, Olivieri, Jacopo, Marcheselli, Luigi, Guerra, Luca, Ferrero, Simone, Arcaini, Luca, Cavallo, Federica, Kovalchuk, Sofya, Skrypets, Tetiana, Del Giudice, Ilaria, Chauvie, Stephane, Patti, Caterina, Stelitano, Caterina, Ricci, Francesca, Pinto, Antonello, Margiotta Casaluci, Gloria, Zilioli, Vittorio R, Merli, Anna, Ladetto, Marco, Bolis, Silvia, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Anastasia, Antonella, Dondi, Alessandra, Mannina, Donato, and Federico, Massimo

Abstract

PURPOSE We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients with follicular lymphoma who responded to induction immunochemotherapy. METHODS We randomly assigned treatment-naive, advanced-stage, high-tumor burden follicular lymphoma patients to receive standard RM or a response-adapted postinduction approach on the basis of metabolic response and molecular assessment of minimal residual disease (MRD). The experimental arm used three types of postinduction therapies: for complete metabolic response (CMR) and MRD-negative patients, observation; for CMR and MRD-positive (end of induction or follow-up) patients, four doses of rituximab (one per week, maximum three courses) until MRD-negative; and for non-CMR patients, one dose of ibritumomab tiuxetan followed by standard RM. The study was designed as noninferiority trial with progression-free survival (PFS) as the primary end point. RESULTS Overall, 807 patients were randomly assigned. After a median follow-up of 53 months (range, 1-92 months), patients in the standard arm had a significantly better PFS than those in the experimental arm (3-year PFS 86% v 72%; P < .001). The better PFS of the standard versus experimental arm was confirmed in all the study subgroups except non-CMR patients (n =65; P = .274). The 3-year overall survival was 98% (95% CI, 96 to 99) and 97% (95% CI, 95 to 99) in the reference and experimental arms, respectively (P = .238). CONCLUSION A metabolic and molecular response-adapted therapy as assessed in the FOLL12 study was associated with significantly inferior PFS compared with 2-year RM. The better efficacy of standard RM was confirmed in the subgroup analysis and particularly for patients achieving both CMR and MRDnegative.

Published
2022

24. Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study)

Author

Mian, M., Capello, D., Ventre, M. B., Grazio, D., Svaldi, M., Rossi, A., Tsang, R., Gospodarowicz, M. K., Oldani, E., Federico, M., Luminari, S., Marcheselli, L., Pogliani, E. M., Rossini, F., Cabrera, M. E., Martelli, M., Gutierrez-Garcia, G., Busetto, M., Visco, C., Fiegl, M., Rossi, D., Gaidano, G., Cavalli, F., Zucca, E., Rambaldi, A., Cortelazzo, S., and on behalf of the International Extranodal Lymphoma Study Group (IELSG)

Published
2014
Full Text
View/download PDF

28. THE ELDERLY PROGNOSTIC INDEX (EPI) PREDICTS EARLY MORTALITY IN OLDER PATIENTS WITH DLBCL. A SUBSTUDY OF THE ELDERLY PROJECT BY THE FONDAZIONE ITALIANA LINFOMI (FIL)

Author

Merli, F., primary, Tucci, A., additional, Arcari, A., additional, Rigacci, L., additional, Cavallo, F., additional, Cabras, G., additional, Alvarez, I., additional, Fabbri, A., additional, Re, A., additional, Ferrero, S., additional, Puccini, B., additional, Usai, S. V., additional, Ferrari, A., additional, Cencini, E., additional, Pennese, E., additional, Zilioli, V. R., additional, Marino, D., additional, Balzarotti, M., additional, Cox, M. C., additional, Zanni, M., additional, Rocco, A., additional, Lleshi, A., additional, Botto, B., additional, Hohaus, S., additional, Merli, M., additional, Sartori, R., additional, Gini, G., additional, Nassi, L., additional, Musuraca, G., additional, Tani, M., additional, Bottelli, C., additional, Kovalchuk, S., additional, Re, F., additional, Flenghi, L., additional, Molinari, A., additional, Tarantini, G., additional, Chimienti, E., additional, Marcheselli, L., additional, Mammi, C., additional, Luminari, S., additional, and Spina, M., additional

Published
2021
Full Text
View/download PDF

29. BRENTUXIMAB VEDOTIN CONSOLIDATION AFTER AUTOLOGOUS STEM CELLS TRANSPLANTATION FOR HODGKIN LYMPHOMA: A REAL‐LIFE EXPERIENCE BY FONDAZIONE ITALIANA LINFOMI (FIL)

Author

Massaro, F., primary, Pavone, V., additional, Stefani, P. M., additional, Botto, B., additional, Pulsoni, A., additional, Patti, C., additional, Cantonetti, M., additional, Visentin, A., additional, Scalzulli, P. R., additional, Rossi, A., additional, Galimberti, S., additional, Cimminiello, M., additional, Gini, G., additional, Musso, M., additional, Sorio, M., additional, Arcari, A., additional, Zilioli, V. R., additional, Bari, A., additional, Mannina, D., additional, Fabbri, A., additional, Pietrantuono, G., additional, Annibali, O., additional, Tafuri, A., additional, Prete, E., additional, Mulè, A., additional, Barbolini, E., additional, Marcheselli, L., additional, Luminari, S., additional, and Merli, F., additional

Published
2021
Full Text
View/download PDF

30. RESPONSE ADAPTED POST INDUCTION THERAPY IN FOLLICULAR LYMPHOMA: UPDATED RESULTS OF THE FOLL12 TRIAL BY THE FONDAZIONE ITALIANA LINFOMI (FIL)

Author

Luminari, S., primary, Galimberti, S., additional, Versari, A., additional, Tucci, A., additional, Boccomini, C., additional, Farina, L., additional, Zaja, F., additional, Marcheselli, L., additional, Ferrero, S., additional, Arcaini, L., additional, Pulsoni, A., additional, Musuraca, G., additional, Califano, C., additional, Merli, M., additional, Bari, A., additional, Conconi, A., additional, Giudice, I. del, additional, Re, F., additional, Stefani, P. M., additional, Usai, S. V., additional, Perrone, T., additional, Gini, G., additional, Falini, B., additional, Gattei, V., additional, Manni, M., additional, Ladetto, M., additional, Mannina, D., additional, and Federico, M., additional

Published
2021
Full Text
View/download PDF

31. PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38)

Author

Pirosa, M. C., primary, Orsucci, L., additional, Feugier, P., additional, Tani, M., additional, Ghesquieres, Hervé, additional, Musuraca, G., additional, Baldini, L., additional, Merli, F., additional, Renzis, B., additional, Gyan, E., additional, Gini, G., additional, Marino, D., additional, Gressin, R., additional, Morschhauser, F., additional, Palombi, F., additional, Cavallo, F., additional, Conconi, A., additional, Gouill, S., additional, Tilly, Hervé, additional, Zanni, M., additional, Cabras, M. G., additional, Capochiani, E., additional, Califano, C., additional, Molinari, A. L., additional, Pulsoni, A., additional, Angrilli, F., additional, Cartron, G., additional, Casasnovas, O., additional, Devizzi, L., additional, Haioun, C., additional, Houot, R., additional, Liberati, A. M., additional, Occhini, U., additional, Merli, M., additional, Pietrantuono, G., additional, Re, F., additional, Spina, M., additional, Esposito, F., additional, Bertoni, F., additional, Rossi, D., additional, Ielmini, N., additional, Luminari, S., additional, Cavalli, F., additional, Zucca, E., additional, Stathis, A., additional, and Thieblemont, C., additional

Published
2021
Full Text
View/download PDF

32. PRIMARY EXTRANODAL FOLLICULAR LYMPHOMA IN A LARGE RETROSPECTIVE SURVEY OF THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG31)

Author

Conconi, A., primary, Vannata, B., additional, Janikova, A., additional, Ramirez, A., additional, Bodoni, C. Lobetti, additional, Nowakowski, G., additional, Mian, M., additional, Ferreri, Andrés J.M., additional, Ryan, G., additional, Pangalis, G. A., additional, Cabrera, M. E., additional, Luminari, S., additional, Montoto, S., additional, Tsang, R., additional, Aurer, I., additional, Visco, C., additional, Mazzucchelli, L., additional, Trneny, M., additional, Gaidano, G., additional, Federico, M., additional, Lopez‐Guillermo, A., additional, Pro, B., additional, and Zucca, E., additional

Published
2021
Full Text
View/download PDF

34. DIRECT‐ACTING ANTIVIRALS AS PRIMARY TREATMENT FOR HCV‐ASSOCIATED INDOLENT NON‐HODGKIN LYMPHOMAS: THE PROSPECTIVE BART STUDY OF THE FONDAZIONE ITALIANA LINFOMI

Author

Merli, M., primary, Rattotti, S., additional, Spina, M., additional, Re, F., additional, Motta, M., additional, Piazza, F., additional, Orsucci, L., additional, Ferreri, Andrés J.M., additional, Perbellini, O., additional, Dodero, A., additional, Vallisa, D., additional, Pulsoni, A., additional, Santoro, A., additional, Zuccaro, V., additional, Chimienti, E., additional, Russo, F., additional, Visco, C., additional, Zignego, A. L., additional, Marcheselli, L., additional, Luminari, S., additional, Paulli, M., additional, Bruno, R., additional, and Arcaini, L., additional

Published
2021
Full Text
View/download PDF

35. UPDATED RESULTS OF THE FIL “MIRO” STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD‐DRIVEN IMMUNOTHERAPY IN EARLY‐STAGE FOLLICULAR LYMPHOMA

Author

Pulsoni, A., primary, Tosti, M. E., additional, Ferrero, S., additional, Luminari, S., additional, Dondi, A., additional, Liberati, A. M., additional, Cenfra, N., additional, Renzi, D., additional, Zanni, M., additional, Boccomini, C., additional, Ferreri, A. J., additional, Rattotti, S., additional, Zilioli, V. R., additional, Bernuzzi, P., additional, Bolis, S., additional, Musuraca, G., additional, Nassi, L., additional, Perrone, T., additional, Stelitano, C., additional, Anastasia, A., additional, Corradini, P., additional, Partesotti, G., additional, Re, F., additional, Cencini, E., additional, Mannarella, C., additional, Mannina, D., additional, Molinari, A. L., additional, Tani, M., additional, Annechini, G., additional, Assanto, G. M., additional, Grapulin, L., additional, Guarini, A., additional, Cavalli, M., additional, De Novi, L. A., additional, Ciabatti, E., additional, Mantoan, B., additional, Della Starza, I., additional, Arcaini, L., additional, Ricardi, U., additional, Gattei, V., additional, Galimberti, S., additional, Ladetto, M., additional, Foà, R., additional, and Del Giudice, I., additional

Published
2021
Full Text
View/download PDF

36. EARLY METABOLIC RESPONSE IN FOLLICULAR LYMPHOMA: A SUBSET ANALYSIS OF THE FOLL12 TRIAL BY THE FONDAZIONE ITALIANA LINFOMI (FIL)

Author

Luminari, S., primary, Guerra, L., additional, Durmo, R., additional, Chauvie, S., additional, Peano, S., additional, Franceschetto, A., additional, Fallanca, F., additional, Tarantino, V., additional, Pinto, A., additional, Ghiggi, C., additional, Pulsoni, A., additional, Merli, M., additional, Farina, L., additional, Tani, M., additional, Botto, B., additional, Musuraca, G., additional, Falini, B., additional, Ballerini, F., additional, Stefani, P. M., additional, Bolis, S., additional, Pietrantuono, G., additional, Manni, M., additional, Marcheselli, L., additional, Federico, M., additional, and Versari, A., additional

Published
2021
Full Text
View/download PDF

37. SUBTYPES OF MATURE T AND NK CELL LYMPHOMAS ACCORDING TO 2016 WHO CLASSIFICATION. PRELIMINARY REPORT OF THE INTERNATIONAL PROSPECTIVE T‐CELL PROJECT 2.0

Author

Federico, M, primary, Chiattone, C. S, additional, Prince, H. M, additional, Pavlovsky, A, additional, Manni, M, additional, Civallero, M, additional, Skrypets, T, additional, De Souza, C. A, additional, Hawkes, E. A, additional, Fiad, L, additional, Lymboussakis, A, additional, Tomuleasa, C, additional, Nair, R, additional, Pereira, J, additional, Pereyra, P, additional, Minoia, C, additional, Kryachok, I, additional, de Castro, N. S, additional, Advani, R. H, additional, and Luminari, S, additional

Published
2021
Full Text
View/download PDF

38. DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN LATE‐OCTOGENARIAN (LO) PATIENTS: A SUBSTUDY OF THE “ELDERLY PROJECT” BY THE FONDAZIONE ITALIANA LINFOMI (FIL)

Author

Tucci, A., primary, Merli, F., additional, Fabbri, A., additional, Mancuso, S., additional, Sartori, R., additional, Storti, S., additional, Luminari, S., additional, Mammi, C., additional, Marcheselli, L., additional, Arcari, A., additional, Cavallo, F., additional, Zilioli, V. R., additional, Bottelli, C., additional, Re, A., additional, Gini, G., additional, Cox, M. C., additional, Puccini, B., additional, Pagani, C., additional, Balzarotti, M., additional, Spina, M., additional, and Rossi, G., additional

Published
2021
Full Text
View/download PDF

39. INMIND: A PHASE 3 STUDY OF TAFASITAMAB + LENALIDOMIDE AND RITUXIMAB VS PLACEBO + LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA

Author

Hübel, K., primary, Scholz, C. W., additional, Luminari, S., additional, Salar, A., additional, Wahlin, B. E., additional, Gopal, A. K., additional, Bonnet, C., additional, Trneny, M., additional, Paneesha, S., additional, Manzke, O., additional, Seguy, F., additional, Li, D., additional, and Sehn, L. H., additional

Published
2021
Full Text
View/download PDF

43. Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies

Author

Varettoni, M., Ferrari, A., Frustaci, A. M., Ferretti, V. V., Rizzi, R., Motta, M., Piazza, F., Merli, M., Benevolo, G., Visco, C., Laurenti, L., Ferrero, S., Gentile, M., Del Fabro, V., Abbadessa, A., Klersy, C., Musto, P., Fabbri, N., Deodato, M., Dogliotti, I., Greco, C., Corbingi, A., Luminari, S., Arcaini, L., Rizzi R., Piazza F., Merli M., Laurenti L. (ORCID:0000-0002-8327-1396), Gentile M., Varettoni, M., Ferrari, A., Frustaci, A. M., Ferretti, V. V., Rizzi, R., Motta, M., Piazza, F., Merli, M., Benevolo, G., Visco, C., Laurenti, L., Ferrero, S., Gentile, M., Del Fabro, V., Abbadessa, A., Klersy, C., Musto, P., Fabbri, N., Deodato, M., Dogliotti, I., Greco, C., Corbingi, A., Luminari, S., Arcaini, L., Rizzi R., Piazza F., Merli M., Laurenti L. (ORCID:0000-0002-8327-1396), and Gentile M.

Abstract

We analyzed 160 young Waldenström Macroglobulinemia (WM) patients with a median age of 49 years (range 23-55 years), diagnosed between January 2000 and January 2019 in 14 Italian centers. At diagnosis, 70% of patients were asymptomatic. With a median follow-up of 5.6 years, 57% have been treated. As initial therapy 79% of patients received chemo-immunotherapy, 13% a chemo-free induction and 8% chemotherapy only. At relapse or progression, 6% underwent an autologous stem cell transplantation. Overall, 19% of patients received ibrutinib during the course of the disease. According to IPSSWM, 63% were classified as low risk, 27% as intermediate risk and 10% as high risk. Five-year OS was shorter in high-risk as compared with low or intermediate risk patients (92.9% vs 100% P =.002). According to revised IPSSWM, 92% were classified as very low or low risk and 8% as intermediate risk, with a shorter 5-year OS in the latter group (87.5% vs 100%, P =.028). The OS of young WM patients was not significantly reduced as compared with age-matched, sex-matched and calendar year-matched general population. Early diagnosis, absence of high-risk features in symptomatic patients and high efficacy of modern treatments are the main determinants of the excellent outcome of young WM patients.

Published
2020

48. LENALIDOMIDE AND RITUXIMAB (ReRi) AS FRONT LINE THERAPY OF ELDERLY FRAIL PATIENTS WITH DIFFUSE LARGE B-CELLS LYMPHOMA. FIRST PLANNED INTERIM ANALYSIS OF A PHASE II STUDY OF THE FONDAZIONE ITALIANA LINFOMI (FIL)

Author

Gini, G., primary, Tani, M., additional, Bassan, R., additional, Tucci, A., additional, Ballerini, F., additional, Sampaolo, M., additional, Merli, F., additional, Re, F., additional, Annibali, O., additional, Liberati, A., additional, Visco, C., additional, Arcari, A., additional, Storti, S., additional, Fabbri, A., additional, Musuraca, G., additional, Zilioli, V., additional, Cox, M., additional, and Luminari, S., additional

Published
2019
Full Text
View/download PDF

49. A GENE EXPRESSION-BASED SCORE TO PREDICT INTERIM PET POSITIVITY IN HODGKIN LYMPHOMA PATIENTS TREATED WITH ABVD

Author

Donati, B., primary, Casali, M., additional, Fama, A., additional, Puccini, B., additional, Zanelli, M., additional, Valli, R., additional, Santi, R., additional, Vergoni, F., additional, Ruffini, A., additional, Berti, V., additional, Rigacci, L., additional, Merli, F., additional, Ciarrocchi, A., additional, and Luminari, S., additional

Published
2019
Full Text
View/download PDF

50. IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA

Author

Batlevi, C.L., primary, Sha, F., additional, Alperovich, A., additional, Ni, A., additional, Smith, K., additional, Ying, Z., additional, Hamlin, P., additional, Horwitz, S.M., additional, Kumar, A., additional, Matasar, M., additional, Moskowitz, A.J., additional, Moskowitz, C.H., additional, Noy, A., additional, Palomba, M.L., additional, Portlock, C., additional, Straus, D., additional, Boccomini, C., additional, Tucci, A., additional, Zelenetz, A.D., additional, Seshan, V.E., additional, Luminari, S., additional, Marcheselli, L., additional, Federico, M., additional, and Younes, A., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results